Regenxbio to present interim update of RGX-314 Phase I/IIA trial
Category: #health  By Pankaj Singh  Date: 2019-08-29
  • share
  • Twitter
  • Facebook
  • LinkedIn

Regenxbio to present interim update of RGX-314 Phase I/IIA trial
  • Dr. Jeffery Heier, the primary investigator of the trial, will present the data during the Retina Subspecialty day program held at AAO (American Academy of Ophthalmology) 2019 annual meeting, CA
     
  • The biotechnology firm is also planning to initiate a Phase 2b trial for wet AMD by the end of 2019

Regenxbio Inc., a U.S.-based leading clinical-stage biotechnology company has recently announced that an interim trial update from the Phase I/IIa clinical trial of RGX-314 which is targeted for treating wet AMD (age-related macular degeneration) will be reported at the American Academy of Ophthalmology (AAO) annual meeting in California, during a presentation at the Retina Subspecialty Day program.

As per sources close to the matter, Dr. Jeffery Heier, Director and Co-President of Retina Research at Ophthalmic Consultants & primary investigator of the trial, will present the interim results that include data for all 5 dose cohorts. 

According to Steve Pakola, M.D., Senior V.P. & CMO of Regenxbio, the company is elated by the previously announced positive interim data from the Phase I/IIa trial along with the potential of proprietary NAV® gene therapy as a one-time treatment for wet age-related macular degeneration.

He added that the company is looking forward to demonstrating data from all 5 dose cohorts from the clinical pilot in wet AMD at the coming American Academy of Ophthalmology meeting.

For the record, Regenxbio is a leading bio-technology company focused on improving lives through the potential of gene therapy. The firm’s NAV technology platform is a proprietary AAV (adeno-associated virus) gene delivery platform and consists of exclusive rights to more than 100 novel adeno-associated virus vectors, including AAVrh10, AAV9, AAV8 and AAV7.

Regenxbio and its third-party NAV technology platform licensees are also using NAV for the development of a wide pipeline of candidates in several therapeutic areas.

Source Credit: https://regenxbio.gcs-web.com/news-releases/news-release-details/regenxbio-present-interim-phase-iiia-trial-update-rgx-314



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Aoyuan Healthy to acquire 55% equity interest in Liantianmei
Aoyuan Healthy to acquire 55% equity interest in Liantianmei
By Pankaj Singh

Aoyuan Healthy Life Group Company Ltd., a renowned commercial property operation service and property management service provider based in China, has reportedly announced that Guangdong Xinyuerong Industrial Investment...

Anova Enterprises expands AnovaOS™ to boost clinical development
Anova Enterprises expands AnovaOS™ to boost clinical development
By Pankaj Singh

The U.S-based Anova Enterprises, Inc. (Anova) has reportedly expanded the AnovaOS™ technology platform in order to boost the development of promising novel treatments. The platform brings pharmaceutical companies...

Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
By Pankaj Singh

India’s Drugs Controller General (DCGI) has approved Pune-based Serum Institute of India (SII) to restart the clinical trial of the Oxford/AstraZeneca COVID-19 vaccine in India.